{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"7.6","value":"2.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Time interval in months from date of first treatment until the date of first documented progression of participants.","dispersionType":"Full Range","groups":[{"description":"Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Panitumumab 9 mg/kg IV over 60 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.","id":"OG000","title":"Capecitabine + Panitumumab + Oxaliplatin"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"7.6 months","title":"Overall Progression-free Survival (PFS) for CAPOX and Panitumumab","type":"SECONDARY","unitOfMeasure":"months"}